Glucotrack Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands of US Dollars) (Unaudited)
| Nine-month period ended September 30, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Loss for the period | $(12,503) | $(4,685) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 22 | 21 | ||
| Stock-based compensation | 239 | 260 | ||
| Issuance of restricted shares as compensation towards directors | 178 | 5 | ||
| Linkage difference on principal of loans from stockholders | 1 | 4 | ||
| Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J) | 1,505 | - | ||
| Revaluation expenses related to derivative financial liabilities (Note 3H) | 2 | - | ||
| Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H) | 330 | - | ||
| Changes in assets and liabilities: | ||||
| Other current assets | 80 | (216) | ||
| Accounts payable | 1,129 | 598 | ||
| Other current liabilities | 26 | (134) | ||
| Net cash used in operating activities | (8,991) | (4,147) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of property and equipment | (104) | - | ||
| Net cash used in investing activities | (104) | - | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds received from private placement transaction (Note 3D) | 500 | - | ||
| Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F) | 100 | - | ||
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G) | 360 | - | ||
| Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H) | 4,000 | - | ||
| Net proceeds received from underwritten U.S. public offering | - | 8,730 | ||
| Net cash provided by financing activities | 4,960 | 8,730 | ||
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (11) | (17) | ||
| Change in cash and cash equivalents, and restricted cash | (4,146) | 4,566 | ||
| Cash and cash equivalents, and restricted cash at beginning of the period | 4,502 | 2,331 | ||
| Cash and cash equivalents, and restricted cash, end of period | $356 | $6,897 | ||
| Supplemental disclosure of cash flow activities: | ||||
| (a) Net cash (received) paid during the year for: | ||||
| Interest | $(37) | $ | - | |
| (b) Non-cash investment and financing activities: | ||||
| Deemed dividend upon trigger of down round protection | $ | - | $855 | |
| Recognition of right for use asset against a lease liability (Note 3C) | $79 | $ | - | |
| Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) | $238 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.